Actinium Pharmaceuticals’ (ATNM) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report released on Tuesday morning,Benzinga reports. They currently have a $4.00 target price on the stock.

Separately, Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Stock Down 8.5 %

Shares of NYSE ATNM opened at $1.19 on Tuesday. Actinium Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $10.24. The stock has a market cap of $37.12 million, a price-to-earnings ratio of -0.86 and a beta of 0.10. The company’s fifty day moving average is $1.20 and its 200-day moving average is $1.46.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its position in shares of Actinium Pharmaceuticals by 4.9% during the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after buying an additional 11,812 shares during the period. Geode Capital Management LLC boosted its position in Actinium Pharmaceuticals by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after acquiring an additional 19,843 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Actinium Pharmaceuticals during the 4th quarter worth approximately $32,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 42.7% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock valued at $115,000 after purchasing an additional 27,222 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).